Author

H. Lau

Observed name: H Lau

Observed institution: Novartis (United States)

OpenAlex ID: A5114096334

Risk of progression of nephropathy in a population-based sample with type 2 diabetes

2010 · S. Vupputuri, G.A. Nichols, et al. · Diabetes Research and Clinical Practice · 28

Antihypertensive medication changes and blood pressure goal achievement in a managed care population

2010 · N M Engel-Nitz, T Darkow, et al. · Journal of Human Hypertension · 11

343 Cost-effectiveness of deferasirox in lower-risk myelodysplastic syndrome (MDS) in Canada

2011 · K. El Ouagari, K. Migliaccio-Walle, et al. · Leukemia Research · 2

Pcn293 Post-progression Endpoints in Oncology Trials: Current Clinical and Reimbursement Perspectives

2019 · A. Abraham, R. Shankar, et al. · Value in Health

Psy5 Cost-effectiveness of Deferasirox Versus Deferoxamine in Transfusion-dependent Thalassaemia Patients in Hong Kong—an Initial Analysis

2010 · KK Lee, DP Chow, et al. · Value in Health

Efficacy, Patient Satisfaction and Adherence to Treatment With Deferasirox Doses Of=30 Mg/kg/day in Previously Chelated Iron-overloaded Patients With Beta-thalassaemia Major

2010 · Alì Taher, Mohsen Saleh Elalfy, et al. · UCL Discovery (University College London)

The Impact of Asthma on Quality-of-Life (QoL) and Other Patient-Reported Outcomes: The Patient's Perspective

2006 · S.P. McKenna, D.M. Meads, et al. · Journal of Allergy and Clinical Immunology

Works count: 7

Citation count: 41

H-index: 2

I10-index: 2